| 2026-08-14 | Press release | Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE |
| 2026-07-31 | Press release | Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients |
| 2026-07-31 | Press release | Moleculin Announces Pricing of $9.3 Million Public Offering |
| 2026-07-06 | Press release | Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This |
| 2026-06-30 | Press release | Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater tha |
| 2026-06-05 | Press release | Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML |
| 2026-06-04 | Press release | Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Mean |
| 2026-05-29 | Press release | Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far |
| 2026-05-21 | Press release | Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safe |
| 2026-05-15 | Press release | Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial |
| 2026-05-13 | Press release | Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Be |
| 2026-05-12 | Press release | Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML |
| 2026-05-08 | Press release | Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin |
| 2026-04-23 | Press release | Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models – Data |
| 2026-04-21 | Press release | Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting |
| 2026-04-07 | Press release | Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile |
| 2026-03-23 | Press release | Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout |
| 2026-03-19 | Press release | Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in |
| 2026-03-17 | Press release | Moleculin to Present at 38th Annual ROTH Conference |
| 2026-03-11 | Press release | Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study |
| 2026-02-19 | Press release | Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds |
| 2026-02-18 | Press release | Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) |
| 2026-02-17 | Press release | Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin |
| 2026-02-13 | Press release | Moleculin Launches CEO Corner Platform to Share Strategic Insights |
| 2026-01-13 | Press release | Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects |
| 2026-01-12 | Press release | Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multip |
| 2025-12-17 | Press release | Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurr |
| 2025-12-10 | Press release | Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds |
| 2025-12-09 | Press release | Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pa |
| 2025-12-09 | Press release | Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pa |
| 2025-12-08 | Press release | Moleculin Announces New Annamycin Collaboration in Brain Tumors |
| 2025-11-26 | Press release | Moleculin to Participate in the Virtual Investor Closing Bell Series |
| 2025-11-26 | Press release | Moleculin Announces Reverse Stock Split |
| 2025-11-13 | Press release | Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented |
| 2025-11-12 | Press release | Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill |
| 2025-10-30 | Press release | Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annua |
| 2025-10-29 | Press release | Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin |
| 2025-10-23 | Press release | Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer |
| 2025-09-25 | Press release | Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin |
| 2025-09-09 | Press release | Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial |